Core Insights - The article highlights the successful completion of a 400 million RMB Series D financing round by Jitai Technology, aimed at accelerating strategic initiatives including platform automation, product pipeline development, international collaboration, and talent acquisition [2][4]. Group 1: Company Overview - Jitai Technology, established in 2020, is an AI-driven biotech company focused on innovative nanomaterials, specifically targeting drug delivery and discovery technologies to combat diseases and aging [2]. - The company has developed an AI nanobase model and three core solutions: AiLNP (AI nucleic acid delivery system design platform), AiRNA (AI mRNA sequence design platform), and AiTEM (AI small molecule formulation design platform) [2]. Group 2: Technological Advancements - Jitai Technology has achieved precise targeted delivery capabilities of lipid nanoparticles (LNP) to key tissues and cells such as the liver, lungs, muscles, and immune cells, making significant progress in multi-organ and multi-tissue delivery challenges [3]. - The newly launched OpenCGT platform focuses on addressing industry pain points in precise drug delivery, aiming to lower development barriers and costs while fostering breakthrough CGT therapies [4]. Group 3: Strategic Partnerships and Support - The OpenCGT platform is designed to integrate research capabilities from top universities, resources from major hospitals, and the full R&D chain of CGT innovative pharmaceutical companies in Beijing [4]. - The Beijing Pharmaceutical and Health Industry Investment Fund, established by the Beijing government, aims to inject strong momentum into the development of innovative drugs and medical devices, particularly in emerging fields like cell and gene therapy [4][5]. Group 4: Industry Impact - The article emphasizes the importance of the pharmaceutical and health sector in Beijing's innovation strategy, with a focus on integrating AI with healthcare to drive high-quality development [5]. - The establishment of the OpenCGT platform is expected to accelerate the translation of original innovations and attract top global talent, technology, and capital to enhance Beijing's international competitiveness in the CGT field [5].